Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin for Dysphagia in Children and Adolescents with Prader-Willi Syndrome (DYSMOT)
2021-000094-91Phase 3Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Prader-Willi syndrome (PWS) and dysphagia comparing Intranasal oxytocin with Placebo (2 arms). Primary endpoint: Normalization of OPOD subscores at 12 weeks. Started Apr 2021; status: completed.
02
Drugs
oxytocin
03
Conditions
Prader-Willi syndrome (PWS)dysphagia
Beyond the preview
Go deeper on 2021-000094-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000094-91.